)
)
)
Citius Pharmaceuticals, Inc.
Company Description: Citius Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and unique prescription products. Citius Pharma owns approximately 78% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs.
Goal for Presentation: Educate investors about the company’s key investment merits including its FDA-approved biologic, pipeline of potential first-in-class products, multi-billion-dollar market opportunities, strong partnerships and robust balance sheet, and management’s successful track record of execution.
Additional Comments:
Who referred you to this application?: Emily Longvail
Goal for Presentation: Educate investors about the company’s key investment merits including its FDA-approved biologic, pipeline of potential first-in-class products, multi-billion-dollar market opportunities, strong partnerships and robust balance sheet, and management’s successful track record of execution.
Additional Comments:
Who referred you to this application?: Emily Longvail
What is your next catalyst (value inflection) update?
Further strengthening the financial and operational foundation to support sustained growth
· Continuing to expand LYMPHIR distribution worldwide
· FDA guidance on best path forward to support an NDA for Mino-Lok
Year Founded
2007
Lead Product in Development
Citius Oncology (CTOR) - Commercial-stage product LYMPHIRÔ. A targeted immune therapy for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), launched in December 2025.
· Lead product in development is Mino-LokÒ – Phase 3 trial completed with positive topline results. First and only therapy for salvaging infected central venous catheters (CVCs) for patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs).
Development Phase of Lead Product
Phase III
Exchange
Nasdaq
Ticker
CTXR
CEO/Top Company Official
Leonard Mazur
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
